Kidney Int

• 

  Publication Venue For

  • The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease..  103:1180-1192. 2023
  • The case for treatment of monogenic SRNS with calcineurin inhibitors..  103:839-841. 2023
  • A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury..  103:514-528. 2023
  • Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis..  103:565-579. 2023
  • Tubular-specific expression of HIV protein Vpr leads to severe tubulointerstitial damage accompanied by progressive fibrosis and cystic development..  103:529-543. 2023
  • Viral associations with kidney disease diagnosis and altered kidney metatranscriptome by kidney function..  103:218-222. 2023
  • letter to the editor..  102:1191-1192. 2022
  • Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure..  102:894-903. 2022
  • HIV at 40: kidney disease in HIV treatment, prevention, and cure..  102:740-749. 2022
  • Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease..  102:261-279. 2022
  • A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis..  102:136-148. 2022
  • Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease..  100:1292-1302. 2021
  • A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant..  100:196-205. 2021
  • APOL1-associated kidney disease in northern Nigerians with treated HIV infection..  100:19-21. 2021
  • Removing race from GFR estimates: balancing potential benefits and unintended consequences..  100:11-13. 2021
  • Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296..  99:1244. 2021
  • From confusion to clarity: RAS blockade in patients hospitalized with COVID-19..  99:1059-1061. 2021
  • Best practices for correctly identifying coronavirus by transmission electron microscopy..  99:824-827. 2021
  • Looking back and moving forward..  99:787-790. 2021
  • Mineral bone disease in autosomal dominant polycystic kidney disease..  99:977-985. 2021
  • Innovating and invigorating the clinical trial infrastructure for glomerular diseases..  99:519-523. 2021
  • Patient perspectives and involvement in precision medicine research..  99:511-514. 2021
  • Rationale and design of the Kidney Precision Medicine Project..  99:498-510. 2021
  • Development and evaluation of deep learning-based segmentation of histologic structures in the kidney cortex with multiple histologic stains..  99:86-101. 2021
  • Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement..  99:59-67. 2021
  • Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology..  99:2-4. 2021
  • Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model..  99:161-172. 2021
  • An international cohort study of autosomal dominant tubulointerstitial kidney disease due to REN mutations identifies distinct clinical subtypes..  98:1589-1604. 2020
  • Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296..  98:1621. 2020
  • Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome..  98:1308-1322. 2020
  • Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society..  98:1120-1134. 2020
  • SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule..  98:1296-1307. 2020
  • Back off baclofen when the kidneys don't work..  98:829-831. 2020
  • International consensus definitions of clinical trial outcomes for kidney failure: 2020..  98:849-859. 2020
  • Murine cytomegalovirus dissemination but not reactivation in donor-positive/recipient-negative allogeneic kidney transplantation can be effectively prevented by transplant immune tolerance..  98:147-158. 2020
  • Visualization of putative coronavirus in kidney..  98:231-232. 2020
  • Early experience with COVID-19 in kidney transplantation..  97:1074-1075. 2020
  • Kidney stones: KI at the crossroads of nephrology and urology..  97:1070-1073. 2020
  • Kidney International and the COVID-19 infection..  97:823. 2020
  • The spectrum of kidney biopsy findings in HIV-infected patients in the modern era..  97:1006-1016. 2020
  • Connecting cytokines and cellular signals in the nephron during CKD and hypertension..  97:651-653. 2020
  • Coronary artery disease in chronic kidney disease: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference..  97:642-644. 2020
  • Corrigendum to "Wang L, Chang J-H, Buckley AF, Spurney RF. Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice." Kidney Int. 2019;95:321-332..  97:808-809. 2020
  • Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease..  97:639-642. 2020
  • Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries..  97:143-155. 2020
  • Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study..  97:10-13. 2020
  • Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy..  97:17-19. 2020
  • The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy..  97:119-129. 2020
  • Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer..  96:1417-1421. 2019
  • Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease..  96:1346-1358. 2019
  • Opposing actions of renal tubular- and myeloid-derived porcupine in obstruction-induced kidney fibrosis..  96:1308-1319. 2019
  • Atrial fibrillation and kidney disease: stuck outside the CABANA..  96:1054-1055. 2019
  • Aberrant IgM on T cells: biomarker or pathogenic factor in childhood nephrotic syndrome?.  96:818-820. 2019
  • Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference..  96:836-849. 2019
  • Health-related quality of life in glomerular disease..  95:1209-1224. 2019
  • High-dose IV iron for anemia correction in chronic kidney disease..  95:727-730. 2019
  • HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation..  95:388-404. 2019
  • Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice..  95:321-332. 2019
  • A new BEACON of hope for the treatment of inflammation? The endogenous metabolite itaconate as an alternative activator of the KEAP1-Nrf2 system..  94:646-649. 2018
  • Emerging evidence on renal denervation for the treatment of hypertension..  94:644-646. 2018
  • The Bowman's shield: a tribute to translational science and Detlef Schlöndorff..  94:448-450. 2018
  • There's no place like home: is self-monitoring beneficial in hypertension management?.  94:450-452. 2018
  • Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation..  94:114-125. 2018
  • Gone but not forgotten: resolution of childhood kidney disease and the risk of end-stage kidney disease in adults..  93:1260-1262. 2018
  • Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment..  93:1175-1182. 2018
  • Utility of implantable cardioverter defibrillators in chronic kidney disease..  93:1028-1030. 2018
  • Updated guidelines for the diagnosis and management of high blood pressure: implications for clinical practice in nephrology..  93:768-770. 2018
  • Intersection of salt- and immune-mediated mechanisms of hypertension in the gut microbiome..  93:532-534. 2018
  • Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation..  93:260-269. 2018
  • A novel role for renal epithelial cells and the medullary sodium gradient in the local immune response..  92:1308-1311. 2017
  • Expanding the use of hepatitis C-viremic kidney donors..  92:1031-1033. 2017
  • Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy..  92:780-781. 2017
  • Heavy metal nephropathy: considerations for exposure analysis..  92:548-550. 2017
  • Revisiting the determinants of the glomerular filtration barrier: what goes round must come round..  92:533-536. 2017
  • Losing their footing: Rac1 signaling causes podocyte detachment and FSGS..  92:283-285. 2017
  • Vascular calcification in chronic kidney disease: here to stay?.  92:276-278. 2017
  • Current and potential imaging applications of ferumoxytol for magnetic resonance imaging..  92:47-66. 2017
  • Prophylactic hydration to prevent contrast-induced nephropathy: much ado about nothing?.  92:4-6. 2017
  • The Authors Reply..  91:1518-1519. 2017
  • The sweetest thing: blocking fructose metabolism to prevent acute kidney injury?.  91:998-1000. 2017
  • APOL1: a case in point for replacing race with genetics..  91:768-770. 2017
  • Decreased incidence of end-stage renal disease in American Indians with diabetes: a model for other high-risk populations?.  91:766-768. 2017
  • Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease..  91:711-719. 2017
  • Manipulating the gut microbiome to decrease uremic toxins..  91:521-523. 2017
  • Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression..  91:387-401. 2017
  • A rose by any other name: is stage 3a chronic kidney disease really a disease?.  91:6-8. 2017
  • Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes..  91:204-215. 2017
  • Recycling to discover something new: the role of autophagy in kidney disease..  91:4-6. 2017
  • Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression..  91:196-203. 2017
  • Folic acid supplementation and chronic kidney disease progression..  90:1144-1145. 2016
  • Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease..  90:985-996. 2016
  • Big data in nephrology: promises and pitfalls..  90:240-241. 2016
  • Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?.  90:8-10. 2016
  • Of mice and women: do sex-dependent responses to ischemia-reperfusion injury in rodents have implications for delayed graft function in humans?.  90:10-13. 2016
  • Implementation of standardized follow-up care significantly reduces peritonitis in children on chronic peritoneal dialysis..  89:1346-1354. 2016
  • Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis..  89:1062-1074. 2016
  • In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia..  89:973-975. 2016
  • Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery..  89:939-948. 2016
  • Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease..  89:734-737. 2016
  • Proton pump inhibitors and chronic kidney disease: is it time to sound the alarm?.  89:732-733. 2016
  • We still go for the jugular: implications of the 3SITES central venous catheter study for nephrology..  89:522-524. 2016
  • Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy?.  89:7-9. 2016
  • Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production..  89:135-146. 2016
  • Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?.  89:5-6. 2016
  • Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci..  88:823-832. 2015
  • Renal systems biology of patients with systemic inflammatory response syndrome..  88:804-814. 2015
  • Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation..  88:584-592. 2015
  • When there will never be a randomized controlled trial..  88:220-222. 2015
  • Current treatment practice and outcomes. Report of the hyponatremia registry..  88:167-177. 2015
  • The balance of the evidence on acid-base homeostasis and progression of chronic kidney disease..  88:9-11. 2015
  • Comparative health services research across populations: the unused opportunities in big data..  87:1094-1096. 2015
  • Genome-wide association study of kidney function decline in individuals of European descent..  87:1017-1029. 2015
  • The author replies..  87:859-860. 2015
  • A 4-year survey of the spectrum of renal disease at a National Referral Hospital Outpatient Clinic in Uganda..  87:663. 2015
  • A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation..  87:409-416. 2015
  • Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis..  86:1253-1259. 2014
  • An instrumental variable approach finds no associated harm or benefit with early dialysis initiation in the United States..  86:798-809. 2014
  • Prescriptions for dietary sodium in patients with chronic kidney disease: how will this shake out?.  86:457-459. 2014
  • The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy..  86:259-265. 2014
  • Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways..  85:1290-1302. 2014
  • Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver-derived angiotensinogen..  85:1009-1011. 2014
  • Host APOL1 genotype is independently associated with proteinuria in HIV infection..  84:834-840. 2013
  • Plasma FGF23 levels increase rapidly after acute kidney injury..  84:776-785. 2013
  • Fibroblast growth factor 23 is not associated with and does not induce arterial calcification..  83:1159-1168. 2013
  • Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach..  83:749-756. 2013
  • Choices in kidney transplantation in type 1 diabetes: are there skeletal benefits of the endocrine pancreas?.  83:356-358. 2013
  • Update on fibroblast growth factor 23 in chronic kidney disease..  82:737-747. 2012
  • APOL1 variants in HIV-associated nephropathy: just one piece of the puzzle..  82:259-260. 2012
  • Regarding Maas's editorial letter on serum suPAR levels..  82:492. 2012
  • Net endogenous acid production is associated with a faster decline in GFR in African Americans..  82:106-112. 2012
  • Mechanisms of the proteinuria induced by Rho GTPases..  81:1075-1085. 2012
  • Prehypertension and chronic kidney disease: the ox or the plow?.  81:229-232. 2012
  • Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis..  81:94-99. 2012
  • Clinical trial of focal segmental glomerulosclerosis in children and young adults..  80:868-878. 2011
  • Defining hypercalciuria in nephrolithiasis..  80:777-782. 2011
  • The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy..  80:719-730. 2011
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)..  80:572-586. 2011
  • Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease..  80:288-294. 2011
  • Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease..  79:1370-1378. 2011
  • Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life..  79:678-685. 2011
  • Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics..  79:218-227. 2011
  • FGF23 or PTH: which comes first in CKD ?.  78:947-949. 2010
  • Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy..  77:753-755. 2010
  • Vitamin D deficiency and anemia in early chronic kidney disease..  77:715-720. 2010
  • A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment..  77:239-246. 2010
  • Chronic kidney disease, hypovitaminosis D, and mortality in the United States..  76:977-983. 2009
  • Decreased pulse pressure during hemodialysis is associated with improved 6-month outcomes..  76:1098-1107. 2009
  • A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease..  76:705-716. 2009
  • Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease..  76:652-658. 2009
  • The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy..  75:428-434. 2009
  • DRIVE it home: making the case for prospective economic data collection in randomized clinical trials..  74:1507-1509. 2008
  • Physician access and early nephrology care in elderly patients with end-stage renal disease..  74:1596-1602. 2008
  • Negative trials in nephrology: what can we learn?.  74:1121-1127. 2008
  • Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression..  74:930-936. 2008
  • HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells..  74:1049-1058. 2008
  • Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes..  74:791-798. 2008
  • Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease..  73:956-962. 2008
  • Glomerular beta-galactosidase expression following transduction with microsphere-adenoviral complexes..  61:S68-S72. 2002
  • In vivo gene transfer to kidney by lentiviral vector..  61:S32-S36. 2002
  • Polarity of alpha-galactosidase A uptake by renal tubule cells..  61:S52-S55. 2002
  • Reply from the authors..  58:2239. 2000
  • Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2022
  • Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. 2021
  • The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2021
  • Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops. 2020
  • Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018